Digest Network Come funziona
Network
/
Società
Ba
Non verificato

Bayer

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

74 comunicati stampa

Guarda tutti i comunicati
17/06/2025
Attrezzature medico-sanitarie
Salute
Medicina - Varie
Medicina nucleare
Farmaceutica
Industria
Bayer Files for Approval of gadoquatrane in the U.S.
Fonte
Bayer
Emittente
Business Wire
1,00
0
11/06/2025
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Industria
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
Fonte
Bayer
Emittente
Business Wire
1,00
0
03/06/2025
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer
Fonte
Bayer
Emittente
Business Wire
1,00
0
03/06/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Eventi
Industria
Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress
Fonte
Bayer
Emittente
Business Wire
1,00
0
02/06/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
Eventi
Industria
Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated With Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study
Fonte
Bayer
Emittente
Business Wire
1,00
0
30/05/2025
Farmaceutica
Salute
Oncologia
Medicina - Varie
Industria
CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology
Fonte
Bayer
Emittente
Business Wire
1,00
0
30/05/2025
Farmaceutica
Salute
Oncologia
Medicina - Varie
Industria
New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology
Fonte
Bayer
Emittente
Business Wire
1,00
0
28/05/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Industria
U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer
Fonte
Bayer
Emittente
Business Wire
1,00
0
28/05/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
Fonte
Bayer
Emittente
Business Wire
1,00
0
27/05/2025
Sanità
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT
Fonte
Bayer
Emittente
Business Wire
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0